Navigation Links
CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

KING OF PRUSSIA, Pa., May 31, 2011 /PRNewswire/ -- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors. The designations would entitle CSL Behring to exclusively market recombinant factor VIIa fused with albumin in Europe for a period of 10 years if the product at the stage of license application fulfils the orphan drug requirements. Based on the submission of data from the company's Pediatric Investigation Plan, once available, the 10-year market exclusivity may be extended to 12 years.

Under these designations European Medicines Agency (EMA) will also provide CSL Behring with development assistance and with reductions in certain regulatory fees.

"CSL Behring welcomes Orphan Drug Designation for rVIIa-FP as support of our ongoing commitment to developing, manufacturing and marketing products for the treatment of rare and serious diseases, such as hemophilia with inhibitors," said Val Romberg, Senior Vice President, Global Research & Development. "We will continue to work closely with the EMA to make this important therapy available to patients as soon as possible."

An orphan drug designation application has not yet been submitted in the United States.

By providing incentives to the pharmaceutical industry, the EU legislative framework for orphan medicines encourages the development of products intended to diagnose, prevent and treat life-threatening or chronically-debilitating conditions that impact up to 5 in 10,000 people in the European Union. The initiative helps improve access to quality medical care for patients who have rare diseases for which there are few, if any, approved treatments.

About Hemophilia

Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy.

Some patients develop inhibitors, factor VIII or IX neutralizing antibodies which render further replacement therapy ineffective. It has been reported that up to 33% of all severe hemophilia A and up to 6% of all severe hemophilia B patients develop inhibitors.

Patients who have become refractory to replacement factor therapy can be treated with recombinant human factor VIIa. Factor VIIa is an enzyme that can both initiate blood clotting and, at high dose, "bypass" the factor VIII and IX dependent steps involved in effective coagulation. With the current commercially available recombinant product, frequent injections are needed to adequately control or prevent bleeding due to its inherent short half-life.

About the recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

Using a proprietary genetic fusion technology (patents pending), CSL Behring is in the pre-clinical phase of developing a novel fusion protein formed by linking recombinant Factor VIIa with albumin. Because albumin is the most abundant natural protein in plasma and has a very long half-life (i.e., more than 20 days), the CSL Behring fusion protein is expected to exhibit a good tolerability profile and improved pharmacokinetics that may allow for less frequent dosing.

Preclinical studies have confirmed that CSL Behring's rVIIa-FP has favorable pharmacokinetic properties compared to the existing recombinant product. A half-life extension of greater than 8-fold has been observed. The use of a bypassing agent with an extended half-life could offer significant benefit to those affected by hemophilia A or B with inhibitors and may offer patients the opportunity to be treated less frequently than with the currently available product.

CSL Behring's clinical program intends to demonstrate that an extended half-life rVIIa-FP will result in a requirement for fewer doses while providing adequate therapeutic response in patients with hemophilia A and B with inhibitors.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit

Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
C: 484-919-2618
O: 610-878-4209

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
2. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
3. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
4. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
5. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
6. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
7. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
11. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  The fee-for-service reimbursement ... U.S. medical imaging is on its way ... care payer-provider contracts are set to phase ... wake, alter provider-vendor relationships. The shift to ... forward new purchasing frameworks in the medical ...
(Date:11/30/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), a ... drug delivery systems, announced today it has signed definitive ... Incubator of Technologies Co., Ltd. ("HTIT") for exclusive rights ... China , Hong Kong ... were signed at the Israel Knesset (Parliament). ...
(Date:11/30/2015)... 30, 2015 iCAD, Inc. (Nasdaq: ... its latest solutions for advanced image analysis and ... at the Radiological Society of North American (RSNA) ... from November 29 to December 4, 2015. ... iReveal®, an automated breast density assessment solution, PowerLook® ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and ... unit extraction. These techniques and procedures have been in use for many years and ... While Dr. Parsa Mohebi, M.D. has utilized many of these methods over the years, ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the week of ... raise funds for its research, education, support, and advocacy efforts. The campaign is ... , The Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds ...
(Date:11/30/2015)... ... , ... Cycling, running, and walking are regular Sunday activities for many South ... 28, 2016. , That’s when the 7th annual ANF Group Tour de Broward ... and families at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored ...
(Date:11/30/2015)... ... 30, 2015 , ... ChiliPad , Chili Technology’s temperature-controlled ... through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, recommends ChiliPad ... precisely regulates the surface temperature of each side of the bed so that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ ... NJ. He has both advanced training and considerable experience in reconstructive dentistry ... expert in cosmetic dentistry. He is an active Spear Education member providing ...
Breaking Medicine News(10 mins):